Alternative structural projections:
For other salt forms please inquire.
According to Schwede et al. (2015), Sp-8-BnT-cAMPS potently and selectively activates Epac2 over Epac1 both in vitro and in vivo (in vitro AC50 Epac2 = 0.1 μM (1.8 µM for cAMP) and rel. kmax = 7.7 (1 for cAMP)). At concentrations of 25 to 100 µM, it potentiates glucose-induced insulin secretion from primary human islets. Sp-8-BnT-cAMPS has reduced potency to activate PKA. Detailed technical information available. Reference: Schwede et al., PLoS Biol., 13(1): e1002038 (2015) (Link to PLoS Biology).
Related products: Biolog also offers Sp-8-BnT-2'-O-Me-cAMPS (Cat. No. B 056 / "S-223") which has reduced potency compared to Sp-8-BnT-cAMPS, but efficiently discriminates against PKA, as well as the well-established Epac agonist 8-pCPT-2'-O-Me-cAMP (Cat. No. C 041) which selectively activates Epac1 over Epac2 (Schwede et al. 2015).
| Cat. No. | B 046 |
| CAS number | [pending] |
| Purity | > 98% HPLC |
| Salt form | Sodium |
| Storage temperature | -20°C / -4°F |
| Molecular formula | C₁₇H₁₇N₅O₅PS₂ · Na |
| Molecular weight [g/mol] | 489.5 |
| cAMP modified at the exocyclic oxygen | axial (Sp-) |
| Modifications | 8-cAMP |
| Target | PKA (cAK) Activator |
| Lipophilicity | 2.67 |
| Absorption max [nm] | 283 |
| Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹] | 17100 |
- 1. Schwede F., Bertinetti D., Langerijs C. N., Hadders M. A., Wienk H., Ellenbroek J. H., de Koning E. J. P., Bos J. L., Herberg F. W., Genieser H.-G., Janssen R. A.Rehmann H., PLoS Biol., 13, 1 - 26 (2015), "Structure-Guided Design of Selective Epac1 and Epac2 Agonists"
